<DOC>
	<DOCNO>NCT00408369</DOCNO>
	<brief_summary>To evaluate prophylactic activity orally administer DB289 Plasmodium falciparum non-immune healthy volunteer challenge bite five P. falciparum-infected Anopheles stephensi mosquito</brief_summary>
	<brief_title>Prophylactic Antimalarial Activity DB289 Volunteers</brief_title>
	<detailed_description>The primary endpoint study appearance erythrocytic parasite ( parasitemia ) , indicate prophylaxis failure . Parasitemia seek multiple mean , include blood culture , polymerase chain reaction ( PCR ) , Quantitative Buffy Coat ( QBC ) analysis , thick thin blood smear ( detailed method , Appendix II ) . QBC giemsa-stained blood smear analyze real time positive result one sufficient initiate chloroquine treatment . All positive QBC analyse blood smear confirm two experienced observer . On smear , location parasite record use stage micrometer , slide archive available later re-examination . PCR sample collect store later analysis ; culture inoculate maintain 70 day . A positive result one test constitute drug failure .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Age 18 45 year BMI 19 30 ( Appendix IV ) Able provide home address phone number ; work description , address , phone number ; provide name , address , phone number person willing able assist investigator make contact cognate volunteer study period Able willing followup intensively 3 month schedule visit Postmenopausal surgically sterilize woman Score 80 % write exam test malaria knowledge comprehension study Serum red cell support growth P. falciparum vitro ( Appendix V ) Blood type A O Able willing provide write informed consent screening , HIV testing , study participation Clinically significant abnormality screen examination AST , ALT , bilirubin , hemoglobin , hematocrit , prothrombin time , partial thromboplastin time , creatinine outside limit normal defined time test Johns Hopkins Medical Laboratories laboratory evidence HIV infection active viral hepatitis G6PD deficiency , hemoglobin S C Significant medical illness require systemic treatment and/or hospitalization within one month enrollment History chronic medical illness , significant investigator ' judgment Selfdescribed use tobacco History alcohol drug abuse Use prescribe overthecounter medication nutritional supplement within two week enrollment ( vitamin , daily recommend dose , may take study ) Women childbearing potential Blood plasma donation within 2 week enrollment History malaria residence malariaendemic area Allergy mosquito bite Intolerance chloroquine , Malarone , quinine , quinidine , tetracycline Taken antiinfective drug quininecontaining beverage week prior enrollment Currently participate clinical trial , participate drug trial within two week enrollment , plan participate another clinical trial within three month challenge Any factor investigator believe participation volunteer study appropriate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>prophylactic</keyword>
	<keyword>malaria</keyword>
	<keyword>challenge</keyword>
</DOC>